Taysha Gene Therapies Revenue and Competitors
Estimated Revenue & Valuation
- Taysha Gene Therapies's estimated annual revenue is currently $34.6M per year.
- Taysha Gene Therapies's estimated revenue per employee is $338,873
- Taysha Gene Therapies's total funding is $175M.
- Taysha Gene Therapies's current valuation is $366.7M. (January 2022)
Employee Data
- Taysha Gene Therapies has 102 Employees.
- Taysha Gene Therapies grew their employee count by 23% last year.
Taysha Gene Therapies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Patient Advocacy and External Affairs Officer | Reveal Email/Phone |
3 | SVP, Regulatory Affairs | Reveal Email/Phone |
4 | VP, Financial Planning and Analysis | Reveal Email/Phone |
5 | VP, Total Rewards | Reveal Email/Phone |
6 | VP, Marketing, Sales, and HUB Services | Reveal Email/Phone |
7 | VP Translational Sciences | Reveal Email/Phone |
8 | Senior Director, Patient Advocacy and Government Affairs | Reveal Email/Phone |
9 | Senior Director, Head Patient Advocacy | Reveal Email/Phone |
10 | Director, Technical Operations Program Management | Reveal Email/Phone |
Taysha Gene Therapies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Taysha Gene Therapies?
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we hope to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for new cures—to dramatically improve patients' lives.
keywords:N/A
$175M
Total Funding
102
Number of Employees
$34.6M
Revenue (est)
23%
Employee Growth %
$366.7M
Valuation
N/A
Accelerator
Taysha Gene Therapies News
Get Krystal Biotech alerts: This table compares Krystal Biotech and Taysha Gene Therapies' net margins, return on equity and return on assets.
The pink slips keep raining down like confetti in biotech. Taysha Gene Therapies is the latest company to decide to slim down, bidding farewell to 35% of...
When it launched, Taysha had ambitious plans to advance at least 15 projects and bring a new product to market every few years. Now, it intends...
Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batten Hope CLN7 program currently in Phase 1 clinical proo ...
Other Companies in Dallas
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.8M | 102 | 0% | N/A |
#2 | $21.4M | 102 | N/A | N/A |
#3 | $25.6M | 102 | 20% | N/A |
#4 | $17.7M | 102 | -6% | N/A |
#5 | $32.9M | 102 | 1% | N/A |